Janus Henderson Group PLC Purchases 193,688 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Janus Henderson Group PLC lifted its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,380,382 shares of the biotechnology company's stock after acquiring an additional 193,688 shares during the period. Janus Henderson Group PLC owned approximately 7.22% of Ascendis Pharma A/S worth $602,910,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ASND. Wilmington Savings Fund Society FSB acquired a new stake in Ascendis Pharma A/S during the third quarter worth approximately $30,000. Jones Financial Companies Lllp increased its stake in shares of Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 197 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 328 shares during the period. GAMMA Investing LLC boosted its stake in Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 214 shares in the last quarter. Finally, Quarry LP acquired a new stake in Ascendis Pharma A/S in the fourth quarter worth $96,000.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ASND. Morgan Stanley raised shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $180.00 to $250.00 in a research report on Monday, May 5th. Royal Bank of Canada raised their price objective on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. JPMorgan Chase & Co. upped their target price on Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research report on Friday, May 2nd. Cantor Fitzgerald increased their target price on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. Finally, Wedbush boosted their price target on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $216.07.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND opened at $151.25 on Friday. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $183.00. The firm has a 50-day moving average price of $156.12 and a two-hundred day moving average price of $141.46. The firm has a market cap of $9.22 billion, a price-to-earnings ratio of -21.30 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. As a group, sell-side analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.